ReviewDiscover nano2026
Therapeutic application of engineered extracellular vesicles via pulmonary delivery for inflammatory lung disorders.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are promising nanoscale delivery vehicles for targeted therapy of inflammatory lung disorders like pulmonary fibrosis, asthma, acute respiratory distress syndrome (ARDS), and chronic obstructive pulmonary disease (COPD). EVs as carriers of proteins, lipids, and nucleic acids can influence immune responses and promote intercellular communication. EVs can be used for encapsulation of drug owing to their biocompatibility, minimal immunogenicity, and capacity to penetrate biological barriers. Additionally, EVs can be surface modified to obtain hybrid EVs for selective delivery to target site. The EVs can be administered to the lungs via pulmonary route to maximize the therapeutic concentration at the site of inflammation while reducing systemic negative effects. In conclusion, EV-based nanomedicine for pulmonary administration offers focused therapy with lower toxicity, making it a new and effective strategy for the treatment of inflammatory lung disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.